Table 3.
Studies on watch and wait outcomes, n (%)
| Study | n | NA regime | Recurrence | Salvage therapy | Survival post salvage therapy | Survival |
| Habr-Gama et al[57], 2004 | 71 | Long-course radiotherapy w/ 5-FU | Local:2 Distant: 3 | 2 (100) | 100% | OS: 100% DFS: 92% |
| Habr-Gama et al[92], 2014 | 90 | Long course radiotherapy w/ 5-FU | Local: 28 (31%) | 26 (92.8) | OS: 94% | OS: 91% DFS: 68% |
| OnCore Project, 2016[59] | 129 | 45 Gy w/ 5-FU | Local: 44 (34%) | 36 (88) | N/A | OS: 96% at 3 yr DFS: 88% at 3 yr |
| IWWD Consortium, 2015[58] | 880 | Chemoradiotherapy: 91% | Local: 25.2% | 141 (69) | OS: 75.4% DFS: 84% | OS: 85% DFS: 94% |
| Appelt et al[93], 2015 | 40 | Chemoradiotherapy | Local: 25.9% at 2 yr | 9 | OS: 100% at 2 yr DFS: 100% at 2 yr | OS: 100% at 2 years DFS: 70% at 2 years |
| Smith et al[94], 2012 | 32 | Long-course chemoradiotherapy | Local: 6 (18.75) | 6 (100) | OS: 100% at 17 mo | OS: 96% DFS: 88% all at 17 mo |
| Smith et al[95], 2019 | 113 | Local: 22 (19.5) | 22 (100) | DFS: 91% | OS: 73% DFS: 75% | |
| Martens et al[96], 2016 | 100 | Long-Course: 95% Short Course: 5% | Local: 15% Distant: 5% | 13 | OS: 92.3% | OS: 96.6% DFS: 80.6% all after 3 yr |
| Lai et al[97], 2016 | 18 | Chemoradiotherapy | Local: 2 | 2 | 100% | OS: 100% |
| Rijkmans et al[98], 2017 | 38 | External beam radiotherapy and brachytherapy (iridium) | DFS: 42% OS: 63% | |||
| Vuong et al[99], 2007 | 100 | External beam radiotherapy with brachytherapy (iridium) | Local recurrence at 5 yr: 5% | DFS: 65% OS: 70% | ||
| Gerard et al[100], 2019 | 74 | Contact X-ray brachytherapy | 10% at 3 yr | 2 | DFS: 88% | |
| Sun Myint et al[101], 2018 | 83 | Contact X-ray brachytherapy | 13.2% after 2.5 yr (n = 7) | 6 | DFS: 83.1% | |
| Ortholan et al[63], 2012 | 45 | External beam radiotherapy with contact X-ray boost | DFS: 53% OS: 55% |
DFS: Disease-free survival; OS: Overall survival.